Skip to Main Content

Paper Details

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
J Exp Clin Cancer Res
2
2023
CDX, CDX-, CDX-011, GPNMB, MITF, MiT, MiT transcriptional, MiT-RCC, MiT-Renal Cell Carcinoma, Mithramycin A, NVP-BGT226, PI3K, RCC, RCC tumor, TFE3, TFE3-RCC, TFE3-RCC tumor derived cell lines, TFE3-RCC tumor-derived cell lines, TFEB, Tumor-derived cell lines, cancer, human, mTOR, microphthalmia, microphthalmia-associated transcription factor, patients, phosphoinositide-3-kinase, rapamycin, renal cell carcinoma, sporadic RCC, tumor
Author NameAffiliation
Christopher J RickettsCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Daniel R CrooksCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Xiaohu ZhangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS)
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS)
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS)
Marc FerrerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS)
Darawalee WangsaCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Darawalee WangsaCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Danny WangsaCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Danny WangsaCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Thomas RiedCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Thomas RiedCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Maria J MerinoNational Cancer Institute, National Institutes of Health
Maria J MerinoNational Cancer Institute, National Institutes of Health
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS)
William Marston LinehanCenter for Cancer Research, National Cancer Institute, National Institutes of Health
  • 1 - 16

Datasets

Release 1.2